Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy
Simple Summary
Fouquet, G.; Wartski, M.; Dechmi, A.; Willems, L.; Deau-Fischer, B.; Franchi, P.; Descroocq, J.; Deschamps, P.; Blanc-Autran, E.; Clerc, J.; Bouscary, D.; Barreau, S.; Chapuis, N.; Vignon, M.; Cottereau, A.-S. Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers 2021, 13, 4323. https://doi.org/10.3390/cancers13174323
Fouquet G, Wartski M, Dechmi A, Willems L, Deau-Fischer B, Franchi P, Descroocq J, Deschamps P, Blanc-Autran E, Clerc J, Bouscary D, Barreau S, Chapuis N, Vignon M, Cottereau A-S. Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers. 2021; 13(17):4323. https://doi.org/10.3390/cancers13174323
Chicago/Turabian StyleFouquet, Guillemette, Myriam Wartski, Amina Dechmi, Lise Willems, Bénédicte Deau-Fischer, Patricia Franchi, Justine Descroocq, Paul Deschamps, Estelle Blanc-Autran, Jérôme Clerc, Didier Bouscary, Sylvain Barreau, Nicolas Chapuis, Marguerite Vignon, and Anne-Ségolène Cottereau. 2021. "Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy" Cancers 13, no. 17: 4323. https://doi.org/10.3390/cancers13174323